Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BLTE
Upturn stock ratingUpturn stock rating

Belite Bio Inc ADR (BLTE)

Upturn stock ratingUpturn stock rating
$58.55
Last Close (24-hour delay)
Profit since last BUY-5.12%
upturn advisory
SELL
SELL since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/17/2025: BLTE (1-star) is a SELL. SELL since 5 days. Profits (-5.12%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $85

1 Year Target Price $85

Analysts Price Target For last 52 week
$85Target price
Low$43.7
Current$58.55
high$86.53

Analysis of Past Performance

Type Stock
Historic Profit 30.59%
Avg. Invested days 41
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.92B USD
Price to earnings Ratio -
1Y Target Price 85
Price to earnings Ratio -
1Y Target Price 85
Volume (30-day avg) 5
Beta -1.45
52 Weeks Range 43.70 - 86.53
Updated Date 06/29/2025
52 Weeks Range 43.70 - 86.53
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.36

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -22.23%
Return on Equity (TTM) -33.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1776832047
Price to Sales(TTM) -
Enterprise Value 1776832047
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -35.61
Shares Outstanding 32544800
Shares Floating 14993707
Shares Outstanding 32544800
Shares Floating 14993707
Percent Insiders 53.93
Percent Institutions 0.75

Analyst Ratings

Rating 3
Target Price 85
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Belite Bio Inc ADR

stock logo

Company Overview

overview logo History and Background

Belite Bio, Inc. (BLTE) is a biopharmaceutical company, incorporated in 2012, focuses on developing novel therapeutics targeting untreatable diseases, particularly inherited retinal diseases and metabolic diseases. It is based in Taiwan with an ADR (American Depositary Receipt) trading on the NASDAQ.

business area logo Core Business Areas

  • Rare Retinal Diseases: Focuses on developing therapies for Stargardt disease and other inherited retinal diseases that currently have limited or no treatment options.
  • Metabolic Diseases: Developing therapies for conditions linked to metabolic dysfunction, aiming to address underlying causes and improve patient outcomes.

leadership logo Leadership and Structure

The leadership team includes key executives focused on research, development, and clinical operations. The organizational structure is typical of a biotech company, emphasizing R&D and clinical trials.

Top Products and Market Share

overview logo Key Offerings

  • LBS-008 (Tinlarebant): An oral therapy in Phase 3 clinical trials for Stargardt disease. Market share is currently 0% as it's not yet approved, but potential competitors in the future gene therapy space include companies such as REGENXBIO (RGNX) and others developing gene therapies for retinal diseases. Revenues are currently $0.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and regulated, with significant investment in research and development. The rare disease market offers opportunities due to unmet needs, but also faces challenges in clinical trial recruitment and regulatory pathways.

Positioning

Belite Bio is positioned as a company specializing in rare retinal and metabolic diseases. Its competitive advantage lies in its focus on developing therapies for untreatable conditions. Its small size allows it to be nimble but can affect access to funding.

Total Addressable Market (TAM)

The TAM for Stargardt disease and other rare retinal conditions is estimated to be in the billions of dollars. Belite Bio is positioned to capture a significant portion of this market if LBS-008 is approved.

Upturn SWOT Analysis

Strengths

  • Focus on underserved rare disease markets
  • Promising Phase 3 clinical trial results for LBS-008
  • Strong intellectual property portfolio

Weaknesses

  • Reliance on a single key product (LBS-008)
  • Limited revenue stream
  • Small company size limits resources and capabilities

Opportunities

  • Potential for accelerated regulatory approval for rare diseases
  • Partnerships with larger pharmaceutical companies
  • Expansion into other rare disease indications

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from larger pharmaceutical companies
  • Need for additional funding

Competitors and Market Share

competitor logo Key Competitors

  • RGNX
  • AGTC
  • CRIS
  • OCUL

Competitive Landscape

Belite Bio faces intense competition from larger, more established pharmaceutical companies. Its advantages lie in its focus on rare diseases and its innovative approach. However, it lacks the resources of its larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by advancement through clinical trials.

Future Projections: Future growth is contingent on the successful commercialization of LBS-008 and potential expansion into other indications.

Recent Initiatives: Recent initiatives include progressing the Phase 3 trial for LBS-008, securing funding, and exploring strategic partnerships.

Summary

Belite Bio is a biopharmaceutical company focused on developing therapies for rare retinal and metabolic diseases. Its future depends heavily on the success of LBS-008. While the company is currently burning cash to perform R&D, it has potential for significant growth. Its main challenge is competition from larger pharmaceutical companies and funding needs.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and results are not guaranteed. Market share data is estimated based on industry reports and analysis.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Belite Bio Inc ADR

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2022-04-29
Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 25
Full time employees 25

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.